Clinical trials for Head and neck cancer

84 currently recruiting clinical trials
Phase 1 Lung cancer Kidney cancer Head and neck cancer #NCT04777994
Dose d'expansion cohorte combinaison avec inhibiteur PD-1
NSCLC (Non-Small Cell Lung Cancer) Clear cell carcinoma Oral cavity Nasopharynx Oropharynx Hypopharynx Larynx Salivary glands Nasal cavities and sinuses Squamous cell carcinoma Locally Advanced Metastatic 1 2 3 or more Immunotherapy
Systemic Treatment-Naive
4 recruiting sites
Calico Life Sciences LLC
Phase 1 Lung cancer Kidney cancer Head and neck cancer #NCT04777994
Dose d'expansion monothérapie
NSCLC (Non-Small Cell Lung Cancer) Clear cell carcinoma Oral cavity Nasopharynx Oropharynx Hypopharynx Larynx Salivary glands Nasal cavities and sinuses Squamous cell carcinoma Locally Advanced Metastatic 1 2 3 or more Immunotherapy
Systemic Treatment-Naive
4 recruiting sites
Calico Life Sciences LLC
Phase 1 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer Thyroid and adrenal gland cancer #NCT06551142 #2024-513663-10
Phase 1a
Locally Advanced Metastatic Metastatic Castration-resistant 1 2 3 or more
Systemic Treatment-Naive
3 recruiting sites
GlaxoSmithKline
Phase 1 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer #NCT07094204 #2025-522082-29-00
Escalade de dose monothérapie
Locally Advanced Metastatic Metastatic Castration-resistant Other KRAS KRAS G12C KRAS G12D KRAS non G12C 1 2 3 or more
Systemic Treatment-Naive
4 recruiting sites
Astellas Pharma Développement mondial, Inc.
Phase 1 Breast cancer Prostate cancer Kidney cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer #NCT07094204 #2025-522082-29-00
Cohorte extension de dose autres tumeurs
Locally Advanced Metastatic Other KRAS KRAS G12C KRAS G12D KRAS non G12C 1 2 3 or more
Systemic Treatment-Naive
4 recruiting sites
Astellas Pharma Développement mondial, Inc.
Phase 1 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer #NCT06026410
Bras 1 (Tumeurs solides avancées avec altération du gène RAS)
Locally Advanced Metastatic Other KRAS HRAS KRAS G12C KRAS G12D KRAS non G12C NRAS 1 2 3 or more
Systemic Treatment-Naive
3 recruiting sites
Kura Oncologie, Inc.
Phase 1 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer #NCT06179160 #2023-507091-47-00
Locally Advanced Metastatic KRAS G12D 1 2 3 or more
Systemic Treatment-Naive
3 recruiting sites
Incyte Corporation
Phase 1 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer #NCT07094113
Parties 1, 2 et 3a
Locally Advanced Metastatic Other KRAS KRAS G12C KRAS G12D KRAS non G12C 1 2 3 or more
Systemic Treatment-Naive
2 recruiting sites
Amgen
Phase 1 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer #NCT06781983
Locally Advanced Metastatic Other mutation 1 2 3 or more
Systemic Treatment-Naive
2 recruiting sites
Innate Pharma
Phase 1 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer #NCT06619587
Locally Advanced Metastatic Metastatic Castration-resistant KRAS G12D 1 2 3 or more
Systemic Treatment-Naive
3 recruiting sites
Genentech, Inc